Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in Patients With Acute ST-segment Elevation Myocardial Infarction; ICAT Trial

NCT01404507 Phase 4 COMPLETED

The routine use of glycoprotein (Gp) IIb-IIIa inhibitor such as abciximab is not recommended by current ACC/AHA guideline (Class IIb, level of evidence of A). This may be partly due to potential increase of bleeding. Compared bolus injection followed by continuous infusion of Gp IIb-IIIa inhibitor, single bolus administration was proposed to decrease bleeding complication while maintaining decrease ischemic events. It was also reported that direct intracoronary injection of abciximab might be superior to intravenous injection regarding myocardial perfusion. Aspiration thrombectomy is regarded as important adjunctive therapy in the treatment of acute ST-elevation myocardial infarction (IIa, level of evidence of B). We hypothesized that combination of intracoronary abciximab bolus injection and aspiration thrombectomy might enhance adequate myocardial perfusion in patient with acute ST-elevation myocardial infarction. We will determine whether combination of intracoronary abciximab injection and aspiration thrombectomy is superior to each treatment only in terms of myocardial perfusion through index of microcirculatory resistance and cardiac magnetic resonance imaging.

Details

Lead sponsor	Yonsei University
Phase	Phase 4
Status	COMPLETED
Enrolment	40
Start date	2010-12
Completion	2012-02

Conditions

• Acute Myocardial Infarction

Interventions

• Gp 2b 3a inhibitor
• aspiration thrombectomy
• Both use

Primary outcomes

• Index of microcirculatory resistance by fractional flow reserve (FFR) — 1 day
  Immediate measurement of Index of microcirculatory resistance
• Microvascular obstruction by cardiac magnetic resonance — 7 days
  Microvascular obstruction by cardiac magnetic resonance

Countries

South Korea